Ken Griffin Acumen Pharmaceuticals, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 1,900 shares of ABOS stock, worth $5,586. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,900
Previous 500
280.0%
Holding current value
$5,586
Previous $1,000
600.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding ABOS
# of Institutions
84Shares Held
26.8MCall Options Held
319KPut Options Held
86.3K-
Sands Capital Ventures, LLC Arlington, VA3.42MShares$10 Million4.42% of portfolio
-
Franklin Resources Inc San Mateo, CA3.4MShares$9.98 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.63MShares$7.73 Million0.0% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.3MShares$6.76 Million0.24% of portfolio
-
Laurion Capital Management LP New York, NY1.9MShares$5.57 Million0.07% of portfolio
About Acumen Pharmaceuticals, Inc.
- Ticker ABOS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,503,100
- Market Cap $119M
- Description
- Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...